1. Home
  2. PCVX vs HASI Comparison

PCVX vs HASI Comparison

Compare PCVX & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCVX
  • HASI
  • Stock Information
  • Founded
  • PCVX 2013
  • HASI 1981
  • Country
  • PCVX United States
  • HASI United States
  • Employees
  • PCVX N/A
  • HASI N/A
  • Industry
  • PCVX Biotechnology: Pharmaceutical Preparations
  • HASI Real Estate Investment Trusts
  • Sector
  • PCVX Health Care
  • HASI Real Estate
  • Exchange
  • PCVX Nasdaq
  • HASI Nasdaq
  • Market Cap
  • PCVX 4.0B
  • HASI 3.4B
  • IPO Year
  • PCVX 2020
  • HASI 2013
  • Fundamental
  • Price
  • PCVX $33.02
  • HASI $28.19
  • Analyst Decision
  • PCVX Strong Buy
  • HASI Strong Buy
  • Analyst Count
  • PCVX 8
  • HASI 8
  • Target Price
  • PCVX $135.00
  • HASI $38.25
  • AVG Volume (30 Days)
  • PCVX 1.5M
  • HASI 1.0M
  • Earning Date
  • PCVX 11-04-2025
  • HASI 08-07-2025
  • Dividend Yield
  • PCVX N/A
  • HASI 5.96%
  • EPS Growth
  • PCVX N/A
  • HASI N/A
  • EPS
  • PCVX N/A
  • HASI 1.59
  • Revenue
  • PCVX N/A
  • HASI $92,418,000.00
  • Revenue This Year
  • PCVX N/A
  • HASI $187.82
  • Revenue Next Year
  • PCVX N/A
  • HASI $14.06
  • P/E Ratio
  • PCVX N/A
  • HASI $17.75
  • Revenue Growth
  • PCVX N/A
  • HASI N/A
  • 52 Week Low
  • PCVX $27.66
  • HASI $21.98
  • 52 Week High
  • PCVX $121.06
  • HASI $36.56
  • Technical
  • Relative Strength Index (RSI)
  • PCVX 55.75
  • HASI 57.42
  • Support Level
  • PCVX $30.89
  • HASI $27.47
  • Resistance Level
  • PCVX $32.32
  • HASI $28.31
  • Average True Range (ATR)
  • PCVX 1.19
  • HASI 0.58
  • MACD
  • PCVX 0.30
  • HASI 0.03
  • Stochastic Oscillator
  • PCVX 84.68
  • HASI 53.13

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.

HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.

Share on Social Networks: